Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study

• Published in: The lancet respiratory medicine Vol. 5; no. 11; p. 857
• Main Authors: Herazo-Maya, Jose D, Sun, Jiehuan, Molyneaux, Philip L, Li, Qin, Villalba, Julian A, Tzouvelekis, Argyrios, Lynn, Heather, Juan-Guardela, Brenda M, Risquez, Cristobal, Osorio, Juan C, Yan, Xiting, Michel, George, Aurelien, Nachelle, Lindell, Kathleen O, Klesen, Melinda J, Moffatt, Miriam F, Cookson, William O, Zhang, Yingze, Garcia, Joe G N, Noth, Imre, Prasse, Antje, Bar-Joseph, Ziv, Gibson, Kevin F, Zhao, Hongyu, Herzog, Erica L, Rosas, Ivan O, Maher, Toby M, Kaminski, Naftali
• Format: Journal Article
• Language: English
• Published: England 01.11.2017
• Subjects: Aged; Cohort Studies; Female; Gene Expression Profiling - methods; Genetic Markers - genetics; Genetic Testing - methods; Humans; Idiopathic Pulmonary Fibrosis - genetics; Idiopathic Pulmonary Fibrosis - mortality; Leukocytes, Mononuclear; Linear Models; Male; Middle Aged; Oligonucleotide Array Sequence Analysis - methods; Prognosis; Proportional Hazards Models; Risk Assessment - methods; Risk Factors; Time Factors; Vital Capacity

The clinical course of idiopathic pulmonary fibrosis (IPF) is unpredictable. Clinical prediction tools are not accurate enough to predict disease outcomes. We enrolled patients with IPF diagnosis in a six-cohort study at Yale University (New Haven, CT, USA), Imperial College London (London, UK), Uni...